Q1 Earnings Wire,

Monday May 11 2026 PM

13 names on the tape. Mix of commercial reads, catalyst setups, and cash position updates. Light on beat/miss math, heavy on what actually moves the next leg.

CATX, Perspective Therapeutics

Radiopharm 212Pb platform staying the course. Cohort follow-up reads come late 2026, so this print is a runway and partnership check, not a catalyst. Space is hot (BMY/RayzeBio, Lilly/Point, Novartis/Pluvicto franchise), and CATX is one of the cleaner pure-play 212Pb names left. Watch for any J&J or Novartis chatter on the next platform tuck-in.

CPRX, Catalyst Pharmaceuticals

This print is noise. The story is the May 7 Angelini Pharma bid at $31.50, two fair-price investigations filed within hours, and the topper window now open. Q1 confirmed the underlying engine, $755.9M cash with no debt, AGAMREE up 66.6% year over year, FIRDAPSE royalty step-down a structural tailwind. The Q1 strength only sharpens the case the deal is underpriced versus rare disease comps closing at 20-25x EBITDA. Sanofi, Jazz, Recordati, Chiesi are the plausible toppers. Hold for the bid window, not the close spread.

ABCL, AbCellera Biologics

ABCL635 Phase 2 VMS readout sits Q3 2026. That is the real binary. The quarter is fine, $655M total liquidity, platform partnerships intact. Story is whether ABCL transitions from CRO-flavored discovery shop to owned-asset clinical-stage. VMS hot pocket too, BAY 3283142 and fezolinetant comparable read-throughs in play.

FBRX, Forte Biosciences

$172.5M April raise reset the balance sheet. FB102 Phase 2 reads across celiac plus vitiligo plus alopecia areata over the next four quarters. Warning, the prior FB-401 atopic derm flameout still scars the chart. Investors will demand each indication be clean before reweighting. Cash is no longer the risk, execution is.

ENTA, Enanta Pharmaceuticals

Two timed catalysts to track. EDP-978 KIT topline lands Q4 2026, sets the resp franchise reset. And the Pfizer Paxlovid royalty patent decision lands by end of September, that is the binary cash-flow line nobody is talking about loud enough. Q1 was about preserving optionality on both. If Pfizer settles or ENTA wins, the cash story changes overnight.

KYNB, Kyntra Bio (FibroGen rebrand)

Rebrand printed alongside the quarter. FG-3246 mCRPC interim Q4 2026 is the next data read. Roxadustat Phase 3 LR-MDS reads second half. Warning, FibroGen scar tissue is heavy. Anemia cardiac safety overhang, multiple cycles of disappointment. The Kyntra rebrand only matters if the data sticks. China revenue line still core to runway.

ELTX, Elicio Therapeutics

AMPLIFY-7P DFS mid-2026. Blind tell from management was “fewer events than projected,” which is the classic clean ITT signal you want to hear pre-readout. Warning, microcap with concentrated catalyst, position size accordingly. KRAS-mutated PDAC remains one of the highest-need spaces in solid tumor and ELI-002 is the lead lipid-conjugated peptide vaccine still alive.

MGX, Metagenomi Therapeutics

Hemophilia A IND Q4 2026. Cash to Q4 2027. Story remains in vivo gene editing platform behind the next generation of base editors. Q1 print was a runway and milestone confirm, not a catalyst. Warning, broad gene-editing peer scar from BEAM, CRSP, NTLA, VERV, the whole class trades on platform readouts not press releases.

OCS, Oculis Holding

The setup is the cleanest in the batch. DIAMOND OCS-01 DME topline lands June 2026, that is the high-conviction near-term binary. Licaminlimab DED year-end follow-on. Runway out to second half 2029. Three shots on goal in ophthalmology with category leaders (Alcon, Bausch, AbbVie/Allergan) circling the entire neighborhood as buyers. Miami Tier 3 from March, the story has only sharpened since then.

SANA, Sana Biotechnology

Mayo Clinic anchored with a $25M equity check. That validates the program at an institutional level. The data that matters, UP421 14-month T1D data without immunosuppression, is genuinely unprecedented. SC451 and SG293 both read 2026. Warning, SANA has been a stock that punishes optimism between data drops, and the cap structure pre-dilution remains heavy. The 14-month off-immunosuppression number is the franchise validator, do not lose the signal in the share price chop.

TTRX, Turn Therapeutics

GX-03 atopic derm interim Q2 2026, topline mid-2026. Avenue Capital growth facility unlocks $18M on milestones. Warning, sub-$120M mcap, ~23K average daily volume, 1.8% institutional ownership, going concern flag in the 10-K. Board has stated an M&A-focused strategy in writing (Dewhurst appointment release), Redfield is running regulatory operationally. M&A target setup is real but position sizing has to respect liquidity and binary risk. Locked at small short-term slot, not a build.

TNXP, Tonix Pharmaceuticals

TONMYA Q1 product revenue $3.7M on 5,400 scripts. GPO win covering 35M lives is the launch infrastructure step. Cash to early Q2 2027 keeps the runway honest. Warning, TNXP has decades of capital allocation scars and the prescription number off a small base needs Q2 confirmation before anyone gets excited. Watch refill dynamics, not gross dispense.

LENZ, LENZ Therapeutics

Q1 product revenue $1.7M on 25,000 paid scripts, up 19% quarter over quarter. 46,000 cumulative paid scripts launch through Q1. 10,000+ prescribers with 60% writing multiple times. Cash $258.4M. SG&A $45M reflects the full launch spend pulling forward. EMA MAA filed March, MHRA filed April, six ex-US filings total. Sales force expanding from 88 to 117 territories by end of Q2. Sarah Jessica Parker DTC drove VIZZ.com traffic up 10x post national activations. Net loss $41.5M, $1.32 per share. The print read is mixed on first look, headline revenue light against high spend, but repeat prescribers at 60% and quarter over quarter script growth confirm the underlying adoption thesis. Strategic buyers in eye care (Alcon, Bausch and Lomb, AbbVie via Allergan, Santen) still see a launched category-creating asset. The launch quarter optics will hurt the multiple in the short term. The data underneath the multiple is the story.

The takeaways

CPRX is the live deal, watch for a topper not the close spread.

OCS is the cleanest near-term binary in the batch with the June DIAMOND readout.

SANA UP421 14-month off-immunosuppression data is the highest-impact long-tail item.

LENZ launch quarter optics will be loud, the underlying refill and prescriber data is the actual signal.

ENTA Pfizer Paxlovid patent decision by end of September is the unloved binary nobody is positioning for.